Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Target Occupancy Study of Xanamem

Trial Profile

A Target Occupancy Study of Xanamem

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs UE 2343 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 Nov 2018 Status changed from planning to recruiting, according to an Actinogen Medical media release.
    • 03 Aug 2018 New trial record
    • 30 Jul 2018 According to an Actinogen Medical medioa release, this trial is expected to begin in Q4 2018 and results are anticipated in Q2 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top